Genen­tech snares a PhI RAF in­hibitor from Han­mi in $910M deal

Genen­tech chief deal­mak­er James Sabry has found the lat­est ad­di­tion for their ear­ly-stage can­cer drug pipeline at South Ko­rea’s Han­mi. The big Roche sub­sidiary has li­censed the glob­al rights — out­side of Ko­rea — to HM95573, a pan-RAF in­hibitor now in Phase I.

Han­mi is get­ting $80 mil­lion up­front, $830 mil­lion in mile­stones and a chance at part­ner­ing with one of the high­est pro­file teams in can­cer drug de­vel­op­ment. And Genen­tech adds an­oth­er se­lect pro­gram from a busi­ness de­vel­op­ment team that likes to keep a fo­cused ap­proach on fill­ing par­tic­u­lar gaps in a busy pipeline.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.